Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.
Psychiatry Research July 1, 2024 Ana Paula Anzolin, Daniel Prates Baldez, Bruno Braga Montezano et al. 2 citations
This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial need for rapid-onset treatments in severe depression cases. It introduces an innovative approach to administering an NMDA receptor antagonist, significantly advancing psychopharmacological methods for treating suicidal behaviors as distinct entities,...